OTCMKTS:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis $5.15 -0.12 (-2.28%) As of 10/16/2026 10:49 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Interpace Biosciences Stock (OTCMKTS:IDXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Interpace Biosciences alerts:Sign Up Key Stats Today's Range$5.05▼$5.2050-Day Range$5.15▼$8.5052-Week Range$5.05▼$6.43Volume1,752 shsAverage Volume912 shsMarket Capitalization$28.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Interpace Biosciences, Inc. is a molecular diagnostics company focused on helping physicians evaluate cancer risk and make more informed treatment decisions. The company develops and commercializes molecular tests that analyze genetic and other biological information from patient samples. Its diagnostic offerings have included ThyGeNEXT and ThyraMIR, which are designed to help assess indeterminate thyroid nodules, and PancraGEN, a test used in evaluating pancreatic cysts. Interpace has also developed testing and related services for gastrointestinal conditions, including Barrett’s esophagus, as well as biomarker and companion-diagnostic programs through its pharmaceutical services activities. Interpace’s products are intended for use by healthcare providers, hospitals, laboratories and pharmaceutical companies, primarily in the United States. The company was formerly known as Interpace Diagnostics Group, Inc. and adopted the Interpace Biosciences name as it expanded its focus beyond diagnostic testing into broader precision-medicine and biopharmaceutical services.AI Generated. May Contain Errors. Read More Interpace Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreIDXG MarketRank™: 0.301965378105 of 5 starsInterpace Biosciences scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Interpace Biosciences. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioInterpace Biosciences has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Interpace Biosciences has been sold short.Short Interest Ratio / Days to CoverInterpace Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInterpace Biosciences does not currently pay a dividend.Dividend GrowthInterpace Biosciences does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.12 News SentimentInterpace Biosciences has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Interpace Biosciences this week, compared to 2 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Interpace Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders0.93% of the stock of Interpace Biosciences is held by insiders.Percentage Held by Institutions5.73% of the stock of Interpace Biosciences is held by institutions.Read more about Interpace Biosciences' insider trading history. Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDXG Stock News HeadlinesCircuit Breaker Halts Continuous Trading in TAPDI Oksijen’s TNZTP SharesOctober 16 at 7:50 AM | tipranks.comA PDI Cut Is Priced In AlreadyOctober 15 at 1:30 PM | seekingalpha.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 RevenueOctober 14 at 8:29 PM | globenewswire.comPDI: Contrarian Buy When Ideas Are Out Of Favor (Rating Upgrade)October 13, 2026 | seekingalpha.comPDI Gold Seeks ASX Quotation for New Share IssueOctober 12, 2026 | tipranks.comMajor Insider Move at PIMCO Dynamic Signals Growing ConfidenceOctober 8, 2026 | tipranks.comPDI Gold Drilling at Kiniéro Points to Resource Expansion and Longer Mine LifeOctober 4, 2026 | tipranks.comSee More Headlines IDXG Stock Analysis - Frequently Asked Questions How have IDXG shares performed this year? Interpace Biosciences' stock was trading at $6.1510 at the beginning of 2026. Since then, IDXG shares have decreased by 16.3% and is now trading at $5.15. How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (OTCMKTS:IDXG) posted its quarterly earnings data on Monday, August, 10th. The business services provider reported $0.05 earnings per share (EPS) for the quarter. The business services provider had revenue of $9.13 million for the quarter. Interpace Biosciences had a net margin of 67.64% and a trailing twelve-month return on equity of 145.40%. When did Interpace Biosciences' stock split? Interpace Biosciences's stock reverse split on Thursday, August 27th 2026.The 1-5 reverse split was announced on Thursday, August 27th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Interpace Biosciences? Shares of IDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), Block (XYZ), Johnson & Johnson (JNJ) and NVIDIA (NVDA). Company Calendar Last Earnings8/10/2026Today10/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolOTCMKTS:IDXG CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees102Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.40 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$24.58 million Net Margins67.64% Pretax Margin11.06% Return on Equity145.40% Return on Assets87.36% Debt Debt-to-Equity RatioN/A Current Ratio2.22 Quick Ratio2.22 Sales & Book Value Annual Sales$38.73 million Price / Sales0.74 Cash Flow$28.61 per share Price / Cash Flow0.18 Book Value$25.25 per share Price / Book0.20Miscellaneous Outstanding Shares5,540,000Free Float5,490,000Market Cap$28.53 million OptionableNot Optionable Beta0.63 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:IDXG) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDXG Stock Alerts